By: IPP Bureau
Last updated : February 10, 2025 10:31 am
During the quarter, the company posted Revenue from operations at Rs. 5,269 crore as compared to Rs. 4,505 crore in Q3 FY25, posting a growth of 17 per cent
Zydus Lifesciences has reported Q3 FY25 consolidated net profit at Rs. 1,024 crore compared to Rs. 790 crore in Q3 FY24, reflecting a growth of 30 per cent.
During the quarter, the company posted Revenue from operations at Rs. 5,269 crore as compared to Rs. 4,505 crore in Q3 FY25, posting a growth of 17 per cent.
“We are pleased with the sustained growth momentum across our key businesses that has driven our Q3 performance. Our robust product portfolio execution in the US, market share gain in focused therapy segments and brands in India, and strategic leveraging of our global portfolio in International Markets position us well for future growth. We are on track to achieve our fiscal year 2025 goal of double-digit growth across our key businesses, coupled with improved profitability. Looking ahead, we are strategically building growth levers to ensure sustained success, with patient centricity and quality at the core of our operations,” said Dr. Sharvil Patel, Managing Director, Zydus Lifesciences Limited.